TrialJBMR plus2023

Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone-Modifying Agents for Bone Metastases: A Cross-Sectional Study.

Takumi Kaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.